Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies.

Autoimmunity reviews·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Neurology and therapy·2026
Same author

Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: May 12, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K

Multiple Sclerosis Progression and Relapse Activity in Children.

Pietro Iaffaldano1, Emilio Portaccio2, Giuseppe Lucisano1,3

  • 1Department of Translational Biomedicines and Neurosciences, University of Bari Aldo Moro, Bari, Italy.

JAMA Neurology
|November 27, 2023
PubMed
Summary
This summary is machine-generated.

Pediatric-onset multiple sclerosis (MS) patients show lower progression independent of relapse activity (PIRA) rates compared to adults. Early disease-modifying therapy (DMT) initiation is crucial for reducing both PIRA and relapse-associated worsening (RAW) in all MS patients.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

858

Related Experiment Videos

Last Updated: May 12, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

858

Area of Science:

  • Neurology
  • Immunology
  • Clinical Research

Background:

  • Pediatric-onset multiple sclerosis (POMS) accounts for up to 20% of MS cases, with potential for greater repair capacity.
  • Previous assumptions suggested POMS patients were protected against long-term disability.

Purpose of the Study:

  • To compare the incidence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in POMS versus adult-onset MS (AOMS) and late-onset MS (LOMS).
  • To identify factors associated with PIRA and RAW in different MS onset groups.

Main Methods:

  • A cohort study utilizing prospectively acquired data from the Italian MS Register (June 2000 - September 2021).
  • Analysis of longitudinal data from 16,130 patients with MS, comparing POMS, AOMS, and LOMS.
  • Assessment of clinical and MRI features, disease-modifying therapy (DMT) exposure, and time to first DMT.

Main Results:

  • Patients with POMS exhibited less disability, more active disease, and longer DMT exposure compared to AOMS and LOMS.
  • The cumulative incidence of PIRA was lower in POMS (40.4%) compared to AOMS (44.3%) and LOMS (56.8%).
  • Older age at onset, longer disease duration, and shorter DMT exposure were associated with higher PIRA risk. Delayed DMT initiation increased the risk of both PIRA and RAW.

Conclusions:

  • While POMS patients are less likely to exhibit PIRA over a decade, pediatric onset does not fully protect against disease progression.
  • These findings underscore the importance of early DMT initiation for all MS patients to mitigate both PIRA and RAW.
  • DMT initiation was associated with a reduced occurrence of PIRA and RAW, irrespective of age at onset.